AG
FATE icon

Algert Global’s Fate Therapeutics FATE Stock Holding History

Algert Global’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-106,920
Closed -$135K – 1200
2025
Q3 		$135K Buy
+106,920
New +$115K ﹤0.01% 1071
2025
Q1 		– Sell
-65,510
Closed -$108K – 1227
2024
Q4 		$108K Sell
65,510
-101
-0.2% -$254 ﹤0.01% 1114
2024
Q3 		$230K Hold
65,611
– – 0.01% 1049
2024
Q2 		$215K Buy
65,611
+49,931
+318% +$219K 0.01% 1252
2024
Q1 		$115K Sell
15,680
-64,974
-81% -$402K ﹤0.01% 1006
2023
Q4 		$302K Sell
80,654
-11,210
-12% -$26.5K 0.01% 938
2023
Q3 		$195K Sell
91,864
-444,967
-83% -$1.47M 0.01% 971
2023
Q2 		$2.56M Buy
536,831
+156,294
+41% +$863K 0.11% 310
2023
Q1 		$2.17M Buy
+380,537
New +$2.3M 0.1% 316
2022
Q2 		– Sell
-21,356
Closed -$828K – 1261
2022
Q1 		$828K Buy
21,356
+12,245
+134% +$474K 0.05% 600
2021
Q4 		$533K Buy
9,111
+1,190
+15% +$67.5K 0.07% 514
2021
Q3 		$469K Buy
+7,921
New +$621K 0.06% 559
2018
Q2 		– Sell
-17,580
Closed -$172K – 345
2018
Q1 		$172K Buy
+17,580
New +$168K 0.03% 312
2017
Q4 		– Sell
-70,677
Closed -$280K – 317
2017
Q3 		$280K Sell
70,677
-31,492
-31% -$107K 0.06% 264
2017
Q2 		$331K Buy
+102,169
New +$391K 0.09% 241

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Algert Global's FATE Position: Q4 2025 in Review

Algert Global sold out of Fate Therapeutics (FATE) in Q4 2025, closing a stake of 106,920 shares — an estimated $135K sold.

Algert Global first reported a position in FATE in Q2 2017 and held it in 15 quarters. The position peaked at $2.56M in Q2 2023. 146 funds tracked by Wall St. Rank hold FATE as of Q4 2025.

  • Algert Global reported no remaining Fate Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Algert Global sold 106,920 Fate Therapeutics shares in Q4 2025, an estimated $135K.
  • Algert Global first reported a position in Fate Therapeutics in Q2 2017 and held it in 15 quarters.
  • Algert Global's Fate Therapeutics position peaked at $2.56M in Q2 2023.
  • 146 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.